HRP20230809T1 - Liječenje alzheimerove bolesti u određenoj populaciji bolesnika - Google Patents

Liječenje alzheimerove bolesti u određenoj populaciji bolesnika Download PDF

Info

Publication number
HRP20230809T1
HRP20230809T1 HRP20230809TT HRP20230809T HRP20230809T1 HR P20230809 T1 HRP20230809 T1 HR P20230809T1 HR P20230809T T HRP20230809T T HR P20230809TT HR P20230809 T HRP20230809 T HR P20230809T HR P20230809 T1 HRP20230809 T1 HR P20230809T1
Authority
HR
Croatia
Prior art keywords
subject
treatment
preparation
use according
valyl
Prior art date
Application number
HRP20230809TT
Other languages
English (en)
Croatian (hr)
Inventor
Susan ABUSHAKRA
Aidan POWER
Martin TOLAR
John Hey
Jeremy Yu
Petr Kocis
Original Assignee
Alzheon, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58240195&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20230809(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alzheon, Inc. filed Critical Alzheon, Inc.
Publication of HRP20230809T1 publication Critical patent/HRP20230809T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20230809TT 2015-09-10 2016-09-09 Liječenje alzheimerove bolesti u određenoj populaciji bolesnika HRP20230809T1 (hr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562216404P 2015-09-10 2015-09-10
US201662290287P 2016-02-02 2016-02-02
US201662302027P 2016-03-01 2016-03-01
US201662365809P 2016-07-22 2016-07-22
PCT/US2016/051091 WO2017044840A1 (en) 2015-09-10 2016-09-09 Methods of treating neurodegenerative disorders in a particular patient population
EP16845181.3A EP3347002B1 (en) 2015-09-10 2016-09-09 Treatment of alzheimer's disease in a particular patient population

Publications (1)

Publication Number Publication Date
HRP20230809T1 true HRP20230809T1 (hr) 2023-10-27

Family

ID=58240195

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20230809TT HRP20230809T1 (hr) 2015-09-10 2016-09-09 Liječenje alzheimerove bolesti u određenoj populaciji bolesnika

Country Status (21)

Country Link
US (3) US11191742B2 (https=)
EP (2) EP3347002B1 (https=)
JP (4) JP6789579B2 (https=)
KR (2) KR102547164B1 (https=)
CN (3) CN116712422A (https=)
AU (1) AU2016319107B2 (https=)
CA (1) CA2997376C (https=)
DK (1) DK3347002T3 (https=)
ES (1) ES2952727T3 (https=)
FI (1) FI3347002T3 (https=)
HR (1) HRP20230809T1 (https=)
HU (1) HUE062511T2 (https=)
LT (1) LT3347002T (https=)
MD (1) MD3347002T2 (https=)
MX (2) MX392677B (https=)
PL (1) PL3347002T3 (https=)
PT (1) PT3347002T (https=)
RS (1) RS64481B1 (https=)
SI (1) SI3347002T1 (https=)
SM (1) SMT202300250T1 (https=)
WO (1) WO2017044840A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2941415A1 (en) 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
FI3347002T3 (fi) * 2015-09-10 2023-08-10 Alzheon Inc Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa
CN108623501B (zh) 2017-03-21 2022-04-19 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸衍生物及其用途
CN110003058B (zh) 2018-01-04 2022-01-25 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-3,3-二氘-1-丙磺酸晶型、制备方法及用途
IL316611A (en) * 2018-08-01 2024-12-01 Alzheon Inc Sulfopropanoic acid derivatives for treating neurodegenerative disorders
JP7573512B2 (ja) * 2018-08-01 2024-10-25 アルツェオン・インコーポレーテッド 神経変性障害を治療するための方法
CN111170901A (zh) * 2018-11-13 2020-05-19 润佳（苏州）医药科技有限公司 3-((l-缬氨酰基)氨基)-1-丙磺酸晶型、制备方法及其用途
BR112021025504A2 (pt) * 2019-06-17 2022-04-26 Alzheon Inc Métodos para tratar distúrbios neurodegenerativos
CN116059192B (zh) 2019-11-13 2024-10-29 润佳（苏州）医药科技有限公司 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
MX2024007070A (es) * 2021-12-09 2024-08-22 Alzheon Inc Alz-801 para uso en el tratamiento de la enfermedad de alzheimer.
EP4475831A1 (en) * 2022-02-07 2024-12-18 Alzheon, Inc. Alz-801 for use in treating a covid-19 associated neurological symptom

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
JP3265577B2 (ja) 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法
US20050031651A1 (en) 2002-12-24 2005-02-10 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20060079578A1 (en) 2003-06-23 2006-04-13 Julie Laurin Pharmaceutical formulations of amyloid inhibiting compounds
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
WO2005060393A2 (en) 2003-08-11 2005-07-07 California Institute Of Technology Microfluidic large scale integration
CA2611586A1 (en) * 2005-04-12 2007-06-21 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
PT2089417E (pt) 2006-10-12 2015-04-14 Bhi Ltd Partnership Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico
CN102838532A (zh) 2006-11-24 2012-12-26 Ac免疫有限公司 用于治疗与淀粉样物质或淀粉样蛋白有关的疾病的吡唑胺和噻唑胺衍生物
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
EP2322163A1 (en) * 2009-11-03 2011-05-18 Pharnext New therapeutics approaches for treating alzheimer disease
US20120009125A1 (en) 2010-07-06 2012-01-12 Lombard Jay L Apoe4 and apoj biomarker-based prevention and treatment of dementia
JP6250394B2 (ja) 2010-08-19 2017-12-20 バック・インスティテュート・フォー・リサーチ・オン・エイジング 軽度の認知障害（ｍｃｉ）および関連障害の処置方法
EP2847218A4 (en) * 2012-05-08 2015-12-30 Univ Ramot APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
LT2994160T (lt) * 2013-05-06 2019-08-26 Baxalta Incorporated Alzheimerio ligos pogrupių gydymas su iš kelių donorų sumaišytu imunoglobulinu g
RU2724190C2 (ru) * 2014-02-08 2020-06-23 Дженентек, Инк. Способы лечения болезни альцгеймера
CA2941415A1 (en) * 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
FI3347002T3 (fi) * 2015-09-10 2023-08-10 Alzheon Inc Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa

Also Published As

Publication number Publication date
MX2022003128A (es) 2022-08-02
EP4275750A3 (en) 2024-01-17
HUE062511T2 (hu) 2023-11-28
SI3347002T1 (sl) 2023-12-29
JP7128536B2 (ja) 2022-08-31
US11191742B2 (en) 2021-12-07
JP6789579B2 (ja) 2020-11-25
EP3347002B1 (en) 2023-06-07
PT3347002T (pt) 2023-07-27
RS64481B1 (sr) 2023-09-29
KR102412997B1 (ko) 2022-06-23
HK1257874A1 (en) 2019-11-01
CN116712423A (zh) 2023-09-08
US20230414541A1 (en) 2023-12-28
MD3347002T2 (ro) 2023-10-31
MX392677B (es) 2025-03-24
JP2018526407A (ja) 2018-09-13
US20220096406A1 (en) 2022-03-31
SMT202300250T1 (it) 2023-09-06
ES2952727T3 (es) 2023-11-03
MX2018003023A (es) 2018-06-06
KR102547164B1 (ko) 2023-06-22
CA2997376C (en) 2024-05-14
AU2016319107B2 (en) 2021-02-25
CA2997376A1 (en) 2017-03-16
AU2016319107A1 (en) 2018-03-22
CN116712422A (zh) 2023-09-08
FI3347002T3 (fi) 2023-08-10
KR20180051561A (ko) 2018-05-16
EP4275750A2 (en) 2023-11-15
EP3347002A1 (en) 2018-07-18
CN108289870A (zh) 2018-07-17
PL3347002T3 (pl) 2023-11-13
KR20220042480A (ko) 2022-04-05
JP2022145949A (ja) 2022-10-04
EP3347002A4 (en) 2019-04-24
WO2017044840A1 (en) 2017-03-16
LT3347002T (lt) 2023-09-11
DK3347002T3 (da) 2023-08-14
JP2020200352A (ja) 2020-12-17
JP2025065545A (ja) 2025-04-17

Similar Documents

Publication Publication Date Title
HRP20230809T1 (hr) Liječenje alzheimerove bolesti u određenoj populaciji bolesnika
Maggini et al. A combination of high-dose vitamin C plus zinc for the common cold
HRP20200990T1 (hr) Sastavi za poboljšanje stanične vijabilnosti i postupci za njihovu upotrebu
JP2015038135A5 (https=)
MX395710B (es) Composiciones gomosas de multicomponentes con nucleo duro.
HRP20240231T1 (hr) Farmaceutske formulacije inhibitora brutonove tirozin kinaze
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
HRP20171256T1 (hr) Farmaceutski pripravci karbetocina
BR112012019374A2 (pt) composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2014218522A5 (https=)
MX2021016109A (es) Metodos y composiciones particularmente para el tratamiento del trastorno por deficit de atencion.
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
JP2019530706A5 (https=)
ES2681343T3 (es) Composiciones para la mejora de la función cerebral
JP2013501805A5 (https=)
HRP20200142T1 (hr) Postupci i sastavi za liječenje depresije uporabom ciklobenzaprina
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
JP2018039810A5 (https=)
JP2016505050A5 (https=)
HRP20211488T1 (hr) Sastav i metoda za liječenje metaboličkih poremećaja
Mehra et al. Treatment of severe acne with low-dose isotretinoin
HRP20220701T1 (hr) Spojeni benzazepini za liječenje touretteova sindroma
HRP20230735T1 (hr) Betahistin, ili njegova farmaceutski prihvatljiva sol, i inhibitor monoamin oksidaze, za uporabu u liječenju ili prevenciji jednog ili više simptoma vrtoglavice kod subjekta